Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: kaja who wrote (419)	1/4/1999 3:14:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

I think if you read back into the thread you will find some feedback already on that subject...the question was asked a while ago. In fact, I brough up AVGN quite a long time ago on VD's model portfolio thread. AVGN certainly had a great run...but it may have something to do with rumors of buyout by CHIR (pretty sure that was the rumored suitor). I was tempted to chase avgn, but I never saw the rumor repeated on biofind, so I let it go. Getting back to avgn's epo patent, the PR sounds great, but I wonder--if you try and read these things, it is pretty tough to pull out much (if you are not one of the experts) nevertheless, you could try here if you want to give it a shot patents.ibm.com Anyway, you should also check out the yahoo thread. Several good posts and some good banter in the last twenty messages.